nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

11.12.2019 | Original Article – Clinical Oncology

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

verfasst von: Rui Kitadai, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomi

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Although liver metastasis has been known to be associated with poor prognosis, only a few studies have shown an association between liver metastasis and treatment outcomes with immune checkpoint inhibitors (ICI). Furthermore, factors associated with prognosis have remained unclear. The present study therefore evaluates the efficacy of nivolumab, pembrolizumab, and atezolizumab among patients with non-small cell lung cancer (NSCLC) who had liver metastasis and identifies factors correlated with prognosis.

Materials and methods

A total of 215 patients with advanced and recurrent NSCLC who received ICI therapy at a single center were retrospectively reviewed. A total of 41 patients (19.1%) had liver metastasis upon initiation of ICI therapy. Overall, 125, 64, and 26 patients were treated with nivolumab, pembrolizumab, and atezolizumab, respectively.

Results

Among the included patients, those with liver metastasis had shorter overall survival (OS) [hazard ratio (HR), 2.04; 95% CI 1.33–3.13] and progression-free survival (PFS) (HR, 1.89; 95% CI 1.29–1.71) compared to those without the same. Patients with liver metastasis had a response rate (RR) of 22.5%. Among patients with liver metastasis, inferior OS was associated with low albumin, poor Eastern Cooperative Oncology Group performance status, driver mutation, and number of liver metastasis (≥ 5). Moreover, patients with liver metastasis who had good Royal Marsden Hospital (0–1) and Gustave Roussy Immune (0–1) scores showed significantly longer OS and PFS.

Conclusion

Despite the poor outcomes with ICI treatment in patients with advanced and recurrent NSCLC who had liver metastasis, some characteristics among patients with liver metastasis may be associated with prognosis.

Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013 CrossRefPubMed

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175. https://doi.org/10.1200/JCO.2009.26.7609 CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

Brown K, Comisar C, Witjes H et al (2017) Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol 83(6):1216–1226. https://doi.org/10.1111/bcp.13223 CrossRefPubMedPubMedCentral

Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58(7):835–857. https://doi.org/10.1007/s40262-019-00748-2 CrossRefPubMedPubMedCentral

Cibulskis K, Lawrence MS, Carter SL et al (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31(3):213–219. https://doi.org/10.1038/nbt.2514 CrossRefPubMedPubMedCentral

Clark AM, Ma B, Taylor DL, Griffith L, Wells A (2016) Liver metastases: microenvironments and ex vivo models. Exp Biol Med (Maywood). 241(15):1639–1652. https://doi.org/10.1177/1535370216658144 CrossRefPubMedPubMedCentral

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

Funazo T, Nomizo T, Kim YH (2017) Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 12(9):e140–e141. https://doi.org/10.1016/j.jtho.2017.04.027 CrossRefPubMed

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596 CrossRefPubMedPubMedCentral

Mansfield AS, Murphy SJ, Peikert T et al (2016) Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res 22(9):2177–2182. https://doi.org/10.1158/1078-0432.CCR-15-2246 CrossRefPubMed

Matsuda T, The Japan Cancer Surveillance Research Group (2011) Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 41:139–147CrossRefPubMed

Mok TSK, Wu Y-L, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7 CrossRefPubMed

Nakamura Y, Kitano S, Takahashi A et al (2016) Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. 7(47):77404–77415. https://doi.org/10.18632/oncotarget.12677 CrossRefPubMedPubMedCentral

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1—positive non–small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed

Reck M, Mok TSK, Nishio M et al (2019) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with <em> EGFR</em> mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 7(5):387–401. https://doi.org/10.1016/S2213-2600(19)30084-0 CrossRefPubMed

Ren Y, Dai C, Zheng H et al (2016) Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 7(33):53245–53253. https://doi.org/10.18632/oncotarget.10644 CrossRefPubMedPubMedCentral

Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265. https://doi.org/10.1016/S0140-6736(16)32517-X CrossRefPubMed

Shiroyama T, Suzuki H, Tamiya M et al (2018) Clinical characteristics of liver metastasis in nivolumab-treated patients with non-small cell lung cancer. Anticancer Res 38(8):4723–4729. https://doi.org/10.21873/anticanres.12779 CrossRefPubMed

Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–1089. https://doi.org/10.1126/science.aac4255 CrossRefPubMedPubMedCentral

Stroh M, Winter H, Marchand M et al (2017) Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther 102(2):305–312. https://doi.org/10.1002/cpt.587 CrossRefPubMed

Tamiya M, Tamiya A, Inoue T et al (2018) Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS ONE 13(2):1–10. https://doi.org/10.1371/journal.pone.0192227 CrossRef

Torimura T, Sata M, Ueno T et al (1998) Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29(9):986–991. https://doi.org/10.1016/S0046-8177(98)90205-2 CrossRefPubMed

Tumeh PC, Hellmann MD, Hamid O et al (2017) Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5(5):417–424. https://doi.org/10.1158/2326-6066.cir-16-0325 CrossRefPubMedPubMedCentral

Vokes E, Ready N, Felip E et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959–965. https://doi.org/10.1093/annonc/mdy041 CrossRefPubMed

Yamamoto N, Tamura T, Fukuoka M, Saijo N (1999) Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 15(4):737–741PubMed

Titel: The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases
verfasst von: Rui Kitadai
Yusuke Okuma
Taiki Hakozaki
Yukio Hosomi
Publikationsdatum: 11.12.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03104-w

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

Abstract

Objectives

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

A transcriptional metabolic gene-set based prognostic signature is associated with clinical and mutational features in head and neck squamous cell carcinoma

Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis

Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information

Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis

PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie